

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

OLINK PROTEOMICS AB AND  
OLINK PROTEOMICS INC.,

*Plaintiffs,*

v.

ALAMAR BIOSCIENCES, INC.,

*Defendant.*

C.A. No. 23-01303 (MN)

**STIPULATION AND [PROPOSED] ORDER TO STAY ACTION**

WHEREAS, on November 15, 2023, Plaintiffs Olink Proteomics AB and Olink Proteomics Inc. (collectively, “Olink” or “Plaintiffs”) filed this action asserting infringement of U.S. Patent No. 7,883,848 (“the ’848 Patent”) (D.I. 1);

WHEREAS, on April 1, 2024, Defendant Alamar Biosciences, Inc. (“Alamar”) moved to dismiss Olink’s complaint (D.I. 8);

WHEREAS, on January 23, 2025, Magistrate Judge Burke issued a Report and Recommendation (“the Report”) recommending that the Court grant-in-part and deny-in-part Alamar’s motion to dismiss (D.I. 20);

WHEREAS, on February 11, 2025, the Court adopted the Report and granted Olink leave to file an amended complaint within thirty days (D.I. 23);

WHEREAS, on February 18, 2025, the parties stipulated to extend the time for Olink to file an amended complaint to April 10, 2025 (D.I. 24), which the Court granted on February 19, 2025;

WHEREAS, on April 9, 2025, the parties stipulated to extend the time for Olink to file an amended complaint to April 24, 2025 (D.I. 29), which the Court granted on April 10, 2025;

WHEREAS, Alamar filed a petition for *inter partes* review (“IPR”) on the ’848 Patent, which the Patent Trial and Appeal Board (“PTAB”) instituted on March 7, 2025 (IPR2024-01353); and

WHEREAS, the parties conferred and agree that a stay of the above-captioned case at least until a resolution of the above-referenced IPR challenge against the ’848 patent is in the best interests of the parties and promotes judicial economy.

NOW THEREFORE, IT IS HEREBY STIPULATED AND AGREED by the parties, subject to the approval of the Court, that:

1. This case is stayed pending the issuance of the final written decision from the PTAB in IPR2024-01353;
2. All existing case deadlines are hereby vacated; and
3. The parties shall submit a joint status report with the Court advising of the status of the case within thirty days after the issuance of the final written decision from the PTAB in IPR2024-01353.

/s/ Kelly E. Farnan

Kelly E. Farnan (#4395)  
RICHARDS, LAYTON & FINGER, P.A.  
One Rodney Square  
920 North King Street  
Wilmington, DE 19801  
(302) 651-7700  
farnan@rlf.com

/s/ Andrew C. Mayo

John G. Day (#2403)  
Andrew C. Mayo (#5207)  
ASHBY & GEDDES  
500 Delaware Avenue, 8th Floor  
P.O. Box 1150  
Wilmington, DE 19899-0030  
Tel: (302) 654-1888  
jday@ashbygeddes.com  
amayo@ashbygeddes.com

Paul A. Ainsworth (*pro hac vice*)  
William H. Milliken (*pro hac vice*)  
Joseph H. Kim (*pro hac vice*)  
STERNE, KESSLER, GOLDSTEIN  
& FOX P.L.L.C.  
1101 K Street, NW, 10th Floor  
Washington, DC 20005  
(202) 371-2600  
painsworth@sternekessler.com  
wmilliken@sternekessler.com  
josephk@sternekessler.com

*Attorneys for Plaintiffs*  
*Olink Proteomics AB and*  
*Olink Proteomics Inc.*

*Of Counsel:*

S. Christian Platt (*pro hac vice*)  
JONES DAY  
4655 Executive Drive, Suite 1500  
San Diego, CA 92121-3134  
(858) 314-1156  
cplatt@jonesday.com

Jennifer D. Bennett (*pro hac vice*)  
JONES DAY  
555 California Street, 26th Floor  
San Francisco, CA 94104-1503  
(415) 626-5795  
jenniferbennett@jonesday.com

Laura M. Kanouse (*pro hac vice*)  
JONES DAY  
1221 Peachtree Street NE, Suite 400  
Atlanta, GA 30361-3588  
(404) 521-8352  
lkanouse@jonesday.com

Jesse T. Wynn (*pro hac vice*)  
JONES DAY  
901 Lakeside Avenue E.  
Cleveland, OH 44114-1190  
(216) 586-7072  
jwynn@jonesday.com

*Attorneys for Defendant*  
*Alamar Biosciences, Inc.*

IT IS SO ORDERED this \_\_\_\_ day of April 2025.

---

The Honorable Maryellen Noreika  
United States District Judge